Reproduction & fertility最新文献

筛选
英文 中文
COVID-19 vaccine and its effect on sperm. 新冠肺炎疫苗及其对精子的影响。
Reproduction & fertility Pub Date : 2023-01-25 Print Date: 2023-01-01 DOI: 10.1530/RAF-22-0098
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
{"title":"COVID-19 vaccine and its effect on sperm.","authors":"Rujittika Mungmunpuntipantip, Viroj Wiwanitkit","doi":"10.1530/RAF-22-0098","DOIUrl":"10.1530/RAF-22-0098","url":null,"abstract":"","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matrix metalloproteinase-induced cervical extracellular matrix remodelling in pregnancy and cervical cancer. 妊娠和宫颈癌症中基质金属蛋白酶诱导的宫颈细胞外基质重塑。
Reproduction & fertility Pub Date : 2022-08-09 Print Date: 2022-07-01 DOI: 10.1530/RAF-22-0015
Emmanuel Amabebe, Henry Ogidi, Dilly O Anumba
{"title":"Matrix metalloproteinase-induced cervical extracellular matrix remodelling in pregnancy and cervical cancer.","authors":"Emmanuel Amabebe, Henry Ogidi, Dilly O Anumba","doi":"10.1530/RAF-22-0015","DOIUrl":"10.1530/RAF-22-0015","url":null,"abstract":"<p><strong>Abstract: </strong>The phenomenal extracellular matrix (ECM) remodelling of the cervix that precedes the myometrial contraction of labour at term or preterm appears to share some common mechanisms with the occurrence, growth, invasion and metastasis of cervical carcinoma. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are pivotal to the complex extracellular tissue modulation that includes degradation, remodelling and exchange of ECM components, which contribute to homeostasis under normal physiological conditions such as cervical remodelling during pregnancy and puerperium. However, in cancer such as that of the uterine cervix, this extensive network of extracellular tissue modulation is altered leading to disrupted cell-cell and cell-basement membrane adhesion, abnormal tissue growth, neovascularization and metastasis that disrupt homeostasis. Cervical ECM remodelling during pregnancy and puerperium could be a physiological albeit benign neoplasm. In this review, we examined the pathophysiologic differences and similarities in the role of MMPs in cervical remodelling and cervical carcinoma.</p><p><strong>Lay summary: </strong>During pregnancy and childbirth, the cervix, which is the barrel-shaped lower portion of the womb that connects to the vagina, gradually softens, shortens and opens to allow birth of the baby. This process requires structural and biochemical changes in the cervix that are stimulated by enzymes known as matrix metalloproteinases. Interestingly, these enzymes also affect the structural and biochemical framework of the cervix during cervical cancer, although cervical cancers usually occur after infection by human papillomavirus. This review is intended to identify and explain the similarities and differences between the structural and chemical changes in the cervix during pregnancy and childbirth and the changes seen in cervical cancer.</p>","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":"3 3","pages":"R177-R191"},"PeriodicalIF":0.0,"publicationDate":"2022-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endometriosis in transmasculine individuals. 变性人子宫内膜异位症。
IF 2.8
Reproduction & fertility Pub Date : 2022-04-20 eCollection Date: 2022-04-01 DOI: 10.1530/RAF-21-0096
Cecile A Ferrando
{"title":"Endometriosis in transmasculine individuals.","authors":"Cecile A Ferrando","doi":"10.1530/RAF-21-0096","DOIUrl":"10.1530/RAF-21-0096","url":null,"abstract":"<p><p>Transmasculine people are assigned female at birth but identify as male. These patients often are prescribed testosterone therapy as part of their transition. This treatment can affect ovulation and stop menstrual periods. Endometriosis is a common condition that causes pelvic pain in some people born with female pelvic organs. Not a lot is known about transmasculine people and how often endometriosis affects them. Testosterone should help treat if not reduce the incidence of endometriosis. This commentary looks at the current literature in order to help clarify existing knowledge gaps. Transmasculine patients who present for hysterectomy as a surgery to help them affirm themselves in their self-identified gender sometimes report pelvic pain symptoms as well. There are many reasons why patients report pain before surgery, and this can be related to endometriosis, even though this diagnosis is less expected in this group. Providers caring for transmasculine patients should be aware of this.</p>","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":"3 2","pages":"C7-C10"},"PeriodicalIF":2.8,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Did the NICE guideline for progesterone treatment of threatened miscarriage get it right? NICE关于黄体酮治疗先兆流产的指南正确吗?
Reproduction & fertility Pub Date : 2022-04-07 eCollection Date: 2022-04-01 DOI: 10.1530/RAF-21-0122
W Colin Duncan
{"title":"Did the NICE guideline for progesterone treatment of threatened miscarriage get it right?","authors":"W Colin Duncan","doi":"10.1530/RAF-21-0122","DOIUrl":"10.1530/RAF-21-0122","url":null,"abstract":"<p><p>In November 2021, NICE updated its clinical guideline that covers the management of threatened miscarriage in the first trimester. They recommended offering vaginal micronised progesterone twice daily until 16 completed weeks of pregnancy in those with a previous miscarriage. However, the duration of treatment is not evidence based. In the major clinical trial that informed the guideline, there was no benefit in starting progesterone after 9 weeks and the full effect of progesterone was present at 12 weeks of pregnancy. There are theoretical risks impacting offspring health in later life after maternal pharmaceutical progesterone treatment. As the effect of progesterone seems to be complete by 12 weeks of gestation, we should consider carefully whether to follow the guidance and treat up to 16 weeks of pregnancy.</p><p><strong>Lay summary: </strong>In November 2021, new guidelines were published about the management of bleeding in early pregnancy. If someone who has had a previous miscarriage starts bleeding, they should now be treated with progesterone as this slightly reduces the chance of miscarriage. The guideline says progesterone should be given if the pregnancy is in the womb, and potentially normal, until 16 weeks of pregnancy. However, in the big studies looking at progesterone's effect in reducing miscarriage the beneficial effects of progesterone were complete by 12 weeks of pregnancy. At that stage, it is the placenta and not the mother's ovary that makes the progesterone to support the pregnancy. We do not know the long-term effects of giving extra progesterone during pregnancy on the offspring. Some research has raised the possibility that there might be some adverse effects if progesterone is given for too long. Maybe the guidance should have suggested stopping at 12 weeks rather than 16 weeks of pregnancy.</p>","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":"3 2","pages":"C4-C6"},"PeriodicalIF":0.0,"publicationDate":"2022-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信